Latest Asx News

Frontier Digital Ventures has uncovered apparent misappropriation of approximately USD 430,000 within its Colombian business, Fincaraiz, prompting an ongoing investigation and operational safeguards.

Vicinity Centres confirms its distribution reinvestment plan will apply to the FY25 final distribution, offering investors a 1% discount on new securities issued under the plan.

Marquee Resources has successfully closed an oversubscribed $2.51 million placement, underscoring strong investor confidence as it prepares for the next phase of drilling at its Mt Clement Antimony Project.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

FirstWave Cloud Technology is launching its first AI-powered compliance management feature for Open-AudIT, aiming to convert a large base of free users into paying customers through a subscription model integrated with AWS.

EV Resources has signed a strategic Memorandum of Understanding with Wogen Resources and Xcelsior Capital Advisors to fund and advance its Los Lirios Antimony Project in Mexico, aiming to establish a 100 tonne-per-day processing plant.

Unico Silver Limited has raised $25 million through a share placement to accelerate drilling and resource upgrades at its key silver projects in Argentina, aiming to define a major silver equivalent resource.

VGI Partners Global Investments Limited reported a $17.6 million net loss for FY25 but maintained its dividend policy and executed a $73 million share buy-back, signaling confidence amid market challenges.

Neurizon Therapeutics reports encouraging topline results from its Phase 1 Open-Label Extension study of NUZ-001, demonstrating long-term safety and a significant survival advantage in ALS patients. These findings pave the way for the pivotal HEALEY ALS Platform Trial planned for late 2025.

Perpetual Limited is set to record a significant $153.7 million non-cash impairment for FY25, largely driven by challenges in its J O Hambro boutique. This move underscores ongoing asset outflows but leaves liquidity intact.

Felix Group Holdings has completed a fully underwritten A$16 million placement at a premium, aiming to acquire Nexvia and boost its SaaS platform expansion. A follow-up Share Purchase Plan will offer existing shareholders a chance to participate.